What is Actuate Therapeutics?
Actuate Therapeutics operates as a specialized clinical-stage pharmaceutical entity dedicated to the development and commercialization of novel therapeutics. The company's primary asset, elraglusib, represents a cornerstone of its research efforts, targeting complex oncological conditions. By exploring front-line treatment protocols for advanced pancreatic cancer—specifically through combination therapies involving FOLFIRINOX and checkpoint inhibitors—Actuate is positioning itself as a critical player in the precision medicine landscape. Their operational model integrates rigorous clinical validation with a strategic focus on addressing unmet medical needs in oncology, effectively bridging the gap between laboratory innovation and patient-centric therapeutic solutions.
How much funding has Actuate Therapeutics raised?
Actuate Therapeutics has raised a total of $42.9M across 4 funding rounds:
Private Equity
$3M
Series A
$7M
Series B
$28.2M
Stock/Share Issuance
$4.7M
Private Equity (2017): $3M, investors not publicly disclosed
Series A (2018): $7M led by Bios Partners
Series B (2019): $28.2M supported by Tech Coast Angels, DEFTA Partners, Kairos Ventures, and Bios Partners
Stock/Share Issuance (2025): $4.7M, investors not publicly disclosed
Key Investors in Actuate Therapeutics
DEFTA Partners
DEFTA Partners is a global venture investment firm focusing on innovative healthcare and ICT technologies, with a strategic emphasis on transformative therapeutics.
Kairos Ventures
Kairos Ventures provides resources and capital to empower individuals and companies, focusing on health and financial freedom through transformative innovation.
Bios Partners
Bios Partners is a venture capital firm specializing in early-stage biotech, targeting overlooked scientific opportunities across the Central U.S. to bring novel therapeutics to market.
What's next for Actuate Therapeutics?
With the recent capital injection, Actuate Therapeutics is poised to accelerate its clinical study roadmap. The strategic deployment of these funds will likely prioritize the expansion of elraglusib trials, aiming to establish new standards of care for patients with advanced malignancies. As the company scales its operations, the focus will remain on executing high-value clinical milestones that validate the efficacy of its therapeutic candidates. Investors and industry stakeholders are closely monitoring these developments, as the successful completion of these trials could significantly enhance the company's valuation and market footprint in the competitive biotech sector.
See full Actuate Therapeutics company page
